A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease

Atherosclerosis. Supplements
Chris Packard

Abstract

Statins have revolutionized the management of cardiovascular disease (CVD). Reductions in low-density lipoprotein cholesterol (LDL-C) with statin therapy have been shown to reduce significantly the risk of CVD in primary and secondary prevention trials. Recent evidence from clinical trials supports the concept that lower LDL-C levels, below current guideline targets, provide additional protection against cardiovascular (CV) events. In addition evidence is accumulating that increasing high-density lipoprotein cholesterol (HDL-C) and decreasing the level of chronic inflammation are important targets in CVD risk reduction. Recent studies have investigated the effectiveness of statins in terms of their ability to concomitantly reduce LDL-C, increase HDL-C and lower C-reactive protein (CRP). Results demonstrate that the more effective statins have beneficial effects on this triumvirate of potential treatment targets. Furthermore, the overall safety and tolerability profile is comparable among available statins. This paper examines recent data highlighting the role that statins and other lipid-lowering agents can play in this new treatment paradigm.

References

Dec 19, 1990·JAMA : the Journal of the American Medical Association·L Cashin-HemphillD H Blankenhorn
Aug 5, 1988·JAMA : the Journal of the American Medical Association·V ManninenP Koskinen
Apr 24, 1987·JAMA : the Journal of the American Medical Association·K M AndersonD Levy
Nov 28, 1986·JAMA : the Journal of the American Medical Association·W P CastelliW B Kannel
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Jun 22, 1999·The New England Journal of Medicine·G D Sloop
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jun 30, 2001·The New England Journal of Medicine·P M RidkerUNKNOWN Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Jan 22, 2004·The European Journal of General Practice·Carlos BrotonsUNKNOWN International Society of Behavioral Medicine
Mar 30, 2004·Diabetes Care·Matthias B SchulzeFrank B Hu
Apr 6, 2004·Diabetes Research and Clinical Practice·Paul N DurringtonKaren Smith
Apr 9, 2004·The New England Journal of Medicine·Margaret E BrousseauDaniel J Rader
Apr 13, 2004·American Heart Journal·Herbert SchusterUNKNOWN Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Oct 7, 2004·The American Journal of Cardiology·James ShepherdHoward G Hutchinson
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
May 25, 2005·Circulation·Scott M Grundy
Sep 7, 2005·European Heart Journal·Anton F H StalenhoefWim Wilpshaar

❮ Previous
Next ❯

Citations

Aug 9, 2008·Omics : a Journal of Integrative Biology·M T Ravi Subbiah
Jan 5, 2008·European Journal of Clinical Investigation·L PuccettiA Auteri
Sep 12, 2007·Expert Opinion on Therapeutic Targets·Keith Suckling
Mar 20, 2013·Diabetes & Metabolism·L MonnierD Owens
Oct 25, 2007·European Journal of Human Genetics : EJHG·Sietske J M HomsmaJohn J P Kastelein
Apr 25, 2018·Health and Quality of Life Outcomes·Faustina Frempong-AinguahAllan G Hill

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

International Journal of Clinical Practice. Supplement
J TuomilehtoD Kallend
Nihon rinsho. Japanese journal of clinical medicine
Seijiro Mori, Yasushi Saito
Current Atherosclerosis Reports
John A Farmer
Current Opinion in Cardiology
Balkrishna K Singh, Jawahar L Mehta
© 2021 Meta ULC. All rights reserved